Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Phio Pharmaceuticals Corp. PHIO

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$-8.7M
$-8.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2020 · Revenue 0.0 · Net income -8.8
-10M-20M
2007201020132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2019 · Operating -42795.2%
-50000%
200720162025
ROE
FY2025 · ROE -69.9%
-200%-400%-600%
200720162025
Three returns, three denominators.

Each USD of equity lost 70 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -8.0
-5M-10M
200720162025

Total assetsUSD 21.5M
EquityUSD 20.1M
CashUSD 21.0M

Equity funds 94% of total assets.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PHIO, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B◌◌◌◌◌0.00.00.00.00.00.0◌0.00.0◌◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌◌
Income tax $B0.00.00.00.00.00.00.00.0−0.00.00.00.00.0◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌◌
EPS, diluted $◌−9.08−46.76−10.10−12.43−1.92−19.33−57.46−5.52−16.41−2.10−0.79−2.88−5.62−0.28◌◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %−69.9−114.8−116.6−70.1−76.0−93.7−92.2−95.5−196.3−91.1−175.7−229.0———−756.4−378.8−145.2−101.5
Shares out B0.010.000.000.000.010.010.000.000.000.010.070.010.010.160.10◌◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 64 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Eight checks were skipped: the balance sheet is not tagged before 2011. Four checks were skipped: EPS is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image